ENSTILAR
Drug
LEO Pharma Inc.
Total Payments
$4.0M
Transactions
67,145
Doctors
9,250
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $47,988 | 8 | 5 |
| 2022 | $33,318 | 221 | 163 |
| 2021 | $402,311 | 20,904 | 5,709 |
| 2020 | $483,630 | 7,021 | 2,288 |
| 2019 | $697,060 | 9,866 | 2,965 |
| 2018 | $570,685 | 12,650 | 3,323 |
| 2017 | $1.8M | 16,475 | 4,053 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 102 | 56.3% |
| Food and Beverage | $1.1M | 66,523 | 26.1% |
| Consulting Fee | $493,548 | 191 | 12.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118,280 | 77 | 2.9% |
| Space rental or facility fees (teaching hospital only) | $52,025 | 23 | 1.3% |
| Travel and Lodging | $41,441 | 229 | 1.0% |
Payments by Type
Research
$2.3M
102 transactions
General
$1.8M
67,043 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| LONG TERM STUDY LEO 90100 ON THE BODY | LEO Pharma AS | $763,759 | 0 |
| COND. APPROVED THE SAFETY & EFFICACY OF ENSTILAR SPRAY FOAM VS FOAM VEHICLE ON TARGET LESIONS TLSS IN PATIENTS WITH MODERATE PLAQUE PSORIASIS | LEO Pharma Inc. | $477,854 | 1 |
| THE MAINTENANCE EFFECT OF ENSTILAR FOAM IN COMBINATION WITH OTEZLA | LEO Pharma Inc. | $197,758 | 1 |
| PENDING AN OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF ENSTILAR CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE FOAM IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PATIENTS WITH SKIN OF COLOR FITZPATRICK SKIN PHOTOTYPES IV-VI. | LEO Pharma Inc. | $165,202 | 1 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR QD IN PSORIASIS PATIENTS BEING TREATED WITH BIOLOGIC AGENTS | LEO Pharma Inc. | $132,027 | 1 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR CALCIPOTRIENEBETAMETHASONE DIPROPIONATE FOAM, 0.0050.064 QD IN PSORIASIS PATIENTS BEING TREATED WITH ETANERCEPT OR ADALIMUMAB | LEO Pharma Inc. | $126,650 | 1 |
| CELLULAR AND NEUROPHYSIOLOGIC MECHANISMS OF ITCHY PSORIATIC SCALP IN HUMANS AND ASSESSING THE EFFECT ENSTILAR ON REDUCING NEURAL ITCH SENSITIZATION OF THE SCALP | LEO Pharma Inc. | $101,075 | 1 |
| OPEN LABEL, IIS STUDY ON THE EFFICACY & SAFETY OF A 24-WEEK COURSE OF ENSTILAR CALCIPOTRIENEBETAMETHASONE DIPROPIONATE FOAM, 0.0050.064 APPLIED TWICE DAILY IN PATIENTS WITH NAIL PSORIASIS | LEO Pharma Inc. | $86,100 | 1 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR (CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE) FOAM, 0.005%/0.064% QD IN PSORIASIS PATIENTS BEING TREATED WITH ETANERCEPT OR ADALIMUMAB | LEO Pharma Inc. | $70,000 | 1 |
| OPEN LABEL, IIS STUDY ON THE EFFICACY & SAFETY OF A 24-WEEK COURSE OF ENSTILAR (CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE) FOAM, 0.005%/0.064%) APPLIED TWICE DAILY IN PATIENTS WITH NAIL PSORIASIS | LEO Pharma Inc. | $44,479 | 1 |
| OPEN LABEL IIS STUDY ON THE EFFICACY & SAFETY OF A 24-WEEK COURSE OF ENSTILAR (CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE) FOAM 0.005%/0.064%) APPLIED TWICE DAILY IN PATIENTS WITH NAIL PSORIASIS | LEO Pharma Inc. | $41,365 | 1 |
| PENDING: AN OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF ENSTILAR? (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE) FOAM IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PATIENTS WITH SKIN OF COLOR (FITZPATRICK SKIN PHOTOTYPES IV-VI). | LEO Pharma Inc. | $30,000 | 1 |
| THE IMPACT OF ENSTILAR ON THE COST OF A BIOLOGIC SWITCH | LEO Pharma Inc. | $25,000 | 1 |
Top Doctors Receiving Payments for ENSTILAR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Washington, DC | $815,989 | 98 |
| , MD | Dermatology | Lousiville, KY | $688,767 | 34 |
| , MD | Dermatology | East Windsor, NJ | $348,692 | 73 |
| , MD | Dermatology | New York, NY | $204,326 | 16 |
| Boni Elewski | Dermatology | Birmingham, AL | $187,016 | 11 |
| , MD | Dermatology | Miami, FL | $103,601 | 7 |
| , M.D | Dermatology | West Bloomfield, MI | $58,612 | 39 |
| , MD | Dermatology | Winston Salem, NC | $32,989 | 6 |
| , M.D., PHD | Dermatology | Santa Monica, CA | $27,672 | 98 |
| , MD | Procedural Dermatology | Tamarac, FL | $25,637 | 108 |
| , MD | Dermatology | San Francisco, CA | $25,095 | 29 |
| , MD | Clinical & Laboratory Dermatological Immunology | Los Angeles, CA | $23,196 | 17 |
| , DO | MOHS-Micrographic Surgery | Las Vegas, NV | $21,203 | 21 |
| , M.D | Dermatology | Bethesda, MD | $19,600 | 5 |
| , M.D | Dermatology | Irvine, CA | $18,313 | 5 |
| , M.D | Specialist | Belleville, NJ | $18,111 | 43 |
| , MD | Dermatology | New York, NY | $17,970 | 64 |
| Mark Lebwohl | Dermatology | New York, NY | $16,841 | 11 |
| , M.D | MOHS-Micrographic Surgery | Douglasville, GA | $15,827 | 43 |
| , M.D | Dermatology | Norfolk, VA | $14,245 | 9 |
| , MD, PHD | Dermatology | Danbury, CT | $13,542 | 77 |
| , M.D | Dermatology | Dallas, TX | $12,004 | 80 |
| , M.D.PHD | Dermatology | Miami, FL | $10,355 | 30 |
| , M.D | Dermatology | Farmington, CT | $10,173 | 16 |
| , MD | Dermatology | San Diego, CA | $10,040 | 22 |
Ad
Manufacturing Companies
- LEO Pharma Inc. $3.2M
- LEO Pharma AS $826,193
Product Information
- Type Drug
- Total Payments $4.0M
- Total Doctors 9,250
- Transactions 67,145
About ENSTILAR
ENSTILAR is a drug associated with $4.0M in payments to 9,250 healthcare providers, recorded across 67,145 transactions in the CMS Open Payments database. The primary manufacturer is LEO Pharma Inc..
Payment data is available from 2017 to 2023. In 2023, $47,988 was paid across 8 transactions to 5 doctors.
The most common payment nature for ENSTILAR is "Unspecified" ($2.3M, 56.3% of total).
ENSTILAR is associated with 13 research studies, including "LONG TERM STUDY LEO 90100 ON THE BODY" ($763,759).